Dilution of Share Value from Exercise of Stock Options
First written in FY2020. 13 of 19 entries say "Materialised", first in FY2021-Q1. Latest entry: FY2027-H1.
The whole theme swung hardest in 2017: 37 of 68 companies on the "Worse" side.
- FY2027-H1WorsenedAnnual report
「Series 8 Stock Acquisition Rights (approved by the Board of Directors on 18 May 2026)” “Class, description and number of shares underlying the stock acquisition rights (shares) Common shares 22,800” “Series 9 Stock Acquisition Rights (approved by the Board of Directors on 18 May 2026)” “Class, description and number of shares underlying the stock acquisition rights (shares) Common shares 25,000」
Series 8 and Series 9 stock acquisition rights were newly established, with a total of 47,800 shares listed as potentially dilutive shares. - FY2026-H1WorsenedAnnual report
「Series 6 Stock Acquisition Rights (approved by the Board of Directors on 19 May 2025)” “Class, description and number of shares underlying the stock acquisition rights (shares) Common shares 16,400” “Series 7 Stock Acquisition Rights (approved by the Board of Directors on 19 May 2025)” “Class, description and number of shares underlying the stock acquisition rights (shares) Common shares 15,000」
Series 6 and Series 7 stock acquisition rights were newly established, with a total of 31,400 shares listed as potentially dilutive shares. - FY2025-H1MaterialisedAnnual report
「Between 1 August 2024 and 31 August 2024, the exercise of stock acquisition rights increased the total number of issued shares by 200.」
The exercise of stock acquisition rights increased the total number of issued shares by 200 in August 2024, before the filing date. The existing potential dilution has materialized as additional share issuance. - FY2024MaterialisedAnnual report
「Exercise of rights 1,500 1,000 500” “Unexercised balance 1,200 – –」
During the fiscal year ended January 2024, 3,000 stock acquisition rights were exercised, leaving an unexercised balance of 1,200 at the fiscal year-end. The potential dilution from stock acquisition rights has materialized as actual share issuance. - FY2024-Q3MitigatedAnnual report
「① [Terms of the stock-option program] Not applicable. ② [Status of other share acquisition rights] Not applicable.」
The company stated that there were no applicable matters concerning its stock option plan or other stock acquisition rights. The calculation of diluted quarterly net income per share included an increase of 1,485 in the number of common shares. - FY2024-Q2MaterialisedAnnual report
「1 May 2023–31 July 2023 (Note) The increase resulted from the exercise of stock acquisition rights.」
The exercise of stock acquisition rights during the second quarter resulted in the issuance of 1,400 shares, meaning that the potential dilution has materialized as additional share issuance. - FY2024-Q1MaterialisedAnnual report
「1 February 2023–30 April 2023 (Note) 1. The increase resulted from the exercise of stock acquisition rights. 2. Between 1 May 2023 and 31 May 2023, the exercise of stock acquisition rights increased the total number of issued shares by 1,400 and increased share capital and the capital surplus by ¥770 thousand each.」
The exercise of stock acquisition rights during the first quarter increased the total number of issued shares by 1,600, followed by the issuance of a further 1,400 shares in May 2023. The potential dilution has continued to materialize as actual share issuance. - FY2023MaterialisedAnnual report
「The stock options outstanding during the fiscal year ended January 2023 are covered, and the number of stock options is presented on a share-equivalent basis.」
The exercise of stock acquisition rights during the fiscal year resulted in the issuance of 40,600 shares. At the fiscal year-end, the unexercised balances were 2,700 shares for Series 2, 1,100 shares for Series 4 and 500 shares for Series 5. The potential dilution has materialized as additional share issuance. - FY2023-Q3MaterialisedAnnual report
「1 August 2022–31 October 2022 (Note) 1. The increase resulted from the exercise of stock acquisition rights. 2. Between 1 November 2022 and 30 November 2022, the exercise of stock acquisition rights increased the total number of issued shares by 100 and increased share capital and the capital surplus by ¥55 thousand each.」
The exercise of stock acquisition rights during the third quarter increased the number of shares by 17,200, followed by the issuance of a further 100 shares in November. The potential dilution has continued to materialize as actual share issuance. - FY2023-Q2MaterialisedAnnual report
「1 May 2022–31 July 2022 (Note) 1. The increase resulted from the exercise of stock acquisition rights. 2. Between 1 August 2022 and 31 August 2022, the exercise of stock acquisition rights increased the total number of issued shares by 6,000 and increased share capital and the capital surplus by ¥3.3 million each.」
The exercise of stock acquisition rights increased the number of shares by 15,100 during the second quarter, followed by the issuance of a further 6,000 shares in August 2022. The potential dilution has materialized as additional share issuance. - FY2023-Q1MaterialisedAnnual report
「1 February 2022–30 April 2022 (Note) 2. The increase resulted from the exercise of stock acquisition rights. 4. Between 1 May 2022 and 31 May 2022, the exercise of stock acquisition rights increased the total number of issued shares by 15,100 and increased share capital and the capital surplus by ¥8.275 million each.」
The exercise of stock acquisition rights increased the total number of issued shares by 8,200 during the first quarter, followed by a further increase of 15,100 shares in May 2022. The existing potential dilution has materialized as additional share issuance. - FY2022MitigatedAnnual report
「As of the date of filing this document, the number of shares underlying stock options is 53,900, equivalent to 4.1% of the total 1,324,000 issued shares. If these stock options are exercised, new shares may be issued, potentially diluting equity value.」
Potential dilution from stock options decreased from 82,600 shares, or 6.4%, in the previous fiscal year to 53,900 shares, or 4.1%. - FY2022-Q3MaterialisedAnnual report
「Between 1 November 2021 and 30 November 2021, the exercise of stock acquisition rights increased the total number of issued shares by 1,200.」
The exercise of stock acquisition rights increased the total number of issued shares by 1,200 after the quarter-end. The potential dilution has materialized as additional share issuance. - FY2022-Q2MaterialisedAnnual report
「1 May 2021–31 July 2021 (Note) 1. The increase resulted from the exercise of stock acquisition rights. 2. Between 1 August 2021 and 31 August 2021, the exercise of stock acquisition rights increased the total number of issued shares by 4,200.」
The exercise of stock acquisition rights increased the number of shares by 600 during the second quarter, followed by a further increase of 4,200 shares in August 2021. The potential dilution has materialized as additional share issuance. - FY2022-Q1MaterialisedAnnual report
「1 February 2021–30 April 2021 (Note) 1. The increase resulted from the exercise of stock acquisition rights. 2. Between 1 May 2021 and 31 May 2021, the exercise of stock acquisition rights increased the total number of issued shares by 600 and increased share capital and the capital surplus by ¥330 thousand each.」
The exercise of stock acquisition rights resulted in the issuance of 2,000 shares during the quarter, followed by a further 600 shares after the quarter-end. The existing potential dilution has materialized as additional share issuances. - FY2021WorsenedAnnual report
「As of the date of filing this document, the number of shares underlying stock options is 82,600, equivalent to 6.4% of the total 1,292,000 issued shares. If these stock options are exercised, new shares may be issued, potentially diluting equity value.」
The number of shares underlying stock options was 82,600, representing 6.4% of total issued shares, up from 4.9% previously, indicating an increase in potential dilution. - FY2021-Q2MaterialisedAnnual report
「Between 1 August 2020 and 31 August 2020, the total number of issued shares increased by 400 as a result of the exercise of stock acquisition rights.」
The exercise of stock acquisition rights resulted in a further 400 shares being issued after the quarter-end, meaning that the potential dilution materialized as an additional share issuance. - FY2021-Q1MaterialisedAnnual report
「Between 1 May 2020 and 31 May 2020, the exercise of share acquisition rights increased the total number of issued shares by 2,400 and increased both stated capital and capital reserves by ¥1.320 million.」
The exercise of stock acquisition rights resulted in the issuance of 2,400 shares, meaning that the previously disclosed potential dilution of equity value has materialized as an actual share issuance. - FY2020First statedAnnual report
「As of the date of filing this document, the number of shares underlying the stock options is 61,700, representing 4.9% of the total number of issued shares of 1,267,900. If these stock options are exercised, new shares may be issued, potentially diluting the value of the shares.」
Quantifies the potential dilution, showing 61,700 shares underlying the stock options, equivalent to 4.9% of the total number of issued shares.